echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > ESMO Open: Efficacy and safety of Tomuzotuximab vs. Cetuximab as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma

    ESMO Open: Efficacy and safety of Tomuzotuximab vs. Cetuximab as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma

    • Last Update: 2021-09-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Head and neck squamous cell carcinoma (of HNSCC) originated in the upper respiratory digestive tract mucosal epithelial tumors


    Digestive infection

    The RESGEX study is a randomized phase II trial that aims to compare the anti-epidermal growth factor receptor (anti-EGFR) antibody Tomuzotuximab (tomutuximab) and cetuximab (Cetuximab) in combination with chemotherapy for relapse and/ Or the efficacy and safety of first-line treatment of metastatic head and neck squamous cell carcinoma


    In this study, 240 eligible patients were randomly divided into two groups and received Tomuzotuximab + cisplatin + fluorouracil or cetuximab + cisplatin + fluorouracil treatment.


    (A) Progression-free survival (PFS) of the two groups; (B) Overall survival (OS) of the two groups

    (A) Progression-free survival (PFS) of the two groups; (B) Overall survival (OS) of the two groups

    The median progression-free survival of the Tomuzotuximab group and the cetuximab group were 6.


    The median progression-free survival of the Tomuzotuximab group and the cetuximab group were 6.


    PFS and OS of patients grouped by p16 status

    PFS and OS of patients grouped by p16 status

    In the exploratory analysis, the OS of the p16-positive subgroup was significantly longer than that of the p16-negative subgroup (hazard ratio 1.


    The OS of the p16-positive subgroup was significantly longer than that of the p16-negative subgroup .


    Compared with cetuximab, Tomuzotuximab as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma failed to improve the clinical prognosis of patients

    Original source:

    Original source:

    Klinghammer K, Fayette J, Kawecki A et al.


    A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and / or metastatic squamous cell cancer of the head and neck - the RESGEX study

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.